168 results about "Infective disorder" patented technology

This invention relates to anti-CD40 antibodies or antigen-binding fragments thereof that specifically recognize and weakly activate CD40 molecules in humans, cynomolgus monkeys, and mice, as well as immunoconjugates, pharmaceutical compositions, and combination products comprising said anti-CD40 antibodies or antigen-binding fragments thereof. The invention also relates to nucleic acids encoding said anti-CD40 antibodies or antigen-binding fragments thereof and host cells comprising said nucleic acids, and methods for preparing said anti-CD40 antibodies or antigen-binding fragments thereof. Furthermore, the invention relates to the use of said anti-CD40 antibodies or antigen-binding fragments thereof in the prevention or treatment of tumors or infectious diseases in subjects.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The invention discloses a swelling microneedle patch and a preparation method thereof. The swelling microneedle patch comprises a backing and a swelling microneedle array adhered to the backing, the swelling microneedle array comprises a plurality of microneedles; the microneedle is in the shape of a cone or a rectangular pyramid; the height of the microneedle is 100 to 1000 [mu] m; the diameter of the tip end of the microneedle is 5-30 microns; the diameter of the bottom of the microneedle is 50-500 [mu] m; and the center-to-center distance between every two adjacent microneedles is 50-2000 microns. The swelling microneedle patch provided by the invention can overcome the barrier action of cuticle to penetrate subcutaneously and absorb subcutaneous tissue interstitial fluid, and is simple in preparation process, low in cost and high in universality. The patch is combined with a colloidal gold lateral chromatography test strip, so that the limitations that in-vitro diagnosis of infectious diseases depends on a blood sample, professional medical personnel are needed for operation, the subject compliance is poor and the like can be solved, and the patch is suitable for rapid screening and diagnosis of the infectious diseases.

The present application provides detection and prognosis of infectious diseases. In particular, the present application provides fragment length profiles of nucleic acid libraries, methods of generating fragment length profiles of nucleic acid libraries, and methods of using the fragment length profiles for diagnosis and / or prognosis. The present application further provides methods, compositions, and kits for determining the stage or site of infection in a subject.

The invention discloses a method and system for synchronously detecting host chromatin openness and in-vivo microbiome based on transposase, and belongs to the technical field of biological sequencing data analysis. According to the method, transposase is used for selectively fragmenting an open chromatin region of a host, and a microbial genome is almost randomly cut, so that synchronous enrichment of host and microbial DNA is realized; after high-throughput sequencing library construction and double-end sequencing, sequencing data is split into host source and non-host source reads through bioinformatics analysis, host chromatin state and microorganism composition are analyzed respectively, and a microorganism-host epigenetic regulation network is constructed; the invention further provides a matched DNA sequencing library and an analysis system, multi-scene research of infectious diseases, intestinal microecology, tumor microenvironment and the like is supported, a public database can be reanalyzed, and potential microbial interaction signals are mined. According to the method, the host-microorganism interaction research efficiency is remarkably improved, and a high-sensitivity and integrated technical scheme is provided for epigenetic regulation mechanism analysis.

This invention discloses an alkaloid compound and its uses. Specifically, the invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs of compounds of formula (I), and also to pharmaceutical compositions comprising said compounds and their uses. In particular, this alkaloid compound has a significant inhibitory effect on angiogenesis and can be used as a medicament for the prevention or treatment of tumors, inflammation, ophthalmic diseases, abnormal fibrosis or scar formation, cardiovascular and cerebrovascular diseases, nervous system diseases, infectious diseases, metabolic diseases, and diseases related to abnormal angiogenesis in mammals.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Z34B3 and application thereof. The amino acid sequence of the antibacterial peptide Z34B3 provided by the invention is shown as SEQ ID NO: 1, the secondary structure is an alpha helix, the molecular weight is small, and the antibacterial peptide Z34B3 can change the cell membrane permeability of various gram-negative bacteria including pasteurella multocida, escherichia coli and acinetobacter baumannii, inhibit the generation of cell membranes and play antibacterial and bactericidal roles. Moreover, the antibacterial peptide Z34B3 provided by the invention has low hemolytic activity and no cytotoxicity, and can be applied to preparation of products with bacteriostatic and bactericidal effects and preparation of drugs for preventing and / or treating bacterial infectious diseases. Furthermore, the C tail end of the antibacterial peptide Z34B3 is subjected to amidation modification, and compared with non-modification treatment, the stability can be improved.

The present invention relates to cytokine conjugates for the treatment of proliferative and infectious diseases, and discloses interleukin (IL) conjugates (e.g., IL-2 conjugates) and uses in the treatment of one or more indications. Also described are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a sesquiterpene compound and / or its pharmaceutically acceptable salt in the preparation of medicaments for treating or preventing infectious diseases caused by Staphylococcus aureus, particularly in the preparation of medicaments for treating or preventing infectious diseases caused by drug-sensitive or drug-resistant Staphylococcus aureus. The structure of the sesquiterpene compound of this invention is shown in Formula I: [Formula I]. The sesquiterpene compound used in this invention is derived from *Chrysanthemum indicum*, which is widely available and has low production costs. This invention is the first to discover that the sesquiterpene compound shown in Formula I exhibits very good inhibitory activity against Staphylococcus aureus, including very good inhibitory activity against drug-sensitive, drug-neutral, or drug-resistant Staphylococcus aureus.

The invention relates to the field of biological medicine, and provides an anti-virus infection effect and application of RBM22. Specifically, the invention relates to application of the RBM22 protein, a nucleic acid molecule for coding the protein, and an accelerant or a recombinant expression vector of the protein in preparation of products for treating virus infectious diseases and / or diseases and / or symptoms related to virus infection, and also provides a corresponding medicine or a medicine composition of the RBM22 protein and the nucleic acid molecule. The RBM22 can prevent and inhibit virus infection and relieve inflammation and damage of tissues, provides a new target spot for treatment of virus infection, and has a wide application prospect.

Described herein are mushroom compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect the composition comprises an aqueous or solid fraction of a mycelium, a fermented substrate thereof, or a combination thereof optionally combined with one or more buffering agents, ethanol, and water.

This invention relates to an endogenous antimicrobial peptide from bovine milk and its applications. The antimicrobial polypeptide compound VAVALARPKHPIK is derived from endogenously enzymatically hydrolyzed bovine casein, with the amino acid sequence Val-Ala-Val-Ala-Leu-Ala-Arg-Pro-Lys-His-Pro-Ile-Lys. It exhibits broad inhibitory activity against both Gram-positive and Gram-negative bacteria, including *Porphyromonas gingivalis*, *Escherichia coli*, and *Staphylococcus aureus*. This antimicrobial peptide shows promising applications as a health supplement and / or medical device or pharmaceutical for the prevention and / or reduction of infectious diseases, as a food antimicrobial agent, in novel functional foods, pet food and animal feed additives, and in daily chemical products.

A yeast strain of Saccharomyces cerevisiae var. Boulardii for the treatment and / or the prevention of infectious diseases of the oral cavity, such as dental caries and periodontal diseases. This strain can be used either alone or in combination with the inactive dry form of a yeast strain of Saccharomyces cerevisiae.

A method of diagnosing an infectious disease, including determining the severity of the disease, in a subject comprising measuring an expression level of at least one protein selected from the group consisting of TSG-14, AGER, ANG-2 and ST2 in a sample of the subject; and diagnosing the disease based on said expression level. Kits for carrying out the diagnosis are also disclosed.

An antimicrobial peptide having an amino acid sequence selected from SEQ ID NOs: 2-12 is provided. The antimicrobial peptide has antimicrobial activity against Gram-negative bacteria, Campylobacter jejuni, Escherichia coli, Salmonella enterica subsp. enterica serovar typhimurium, Salmonella enterica subsp. enterica serovar choleraesuis, Klebsiella pneumonica, and / or Enterobacter cloacae. A composition, pharmaceutical composition, food additive, cosmetic composition, or hygine product having an antimicrobial peptide including an amino acid sequence selected from SEQ ID NOs: 2-12 is also provided. A method of treating an infectious disease caused by bacteria including a step of administering a pharmaceutical composition having the antimicrobial peptide as an active ingredient is also provided.

The present invention relates to pyridine-2-thiol 1-oxide derivatives and their use as antimicrobial agents in infectious diseases of mammals (humans and animals) caused by fungi or bacteria, in particular belonging to the Mycobacteriaceae family, especially diseases caused by Mycobacterium abscessus or Mycobacterium tuberculosis.

The invention relates to the technical fields of medicines and luminescent materials. The invention discloses a 1, 6-naphthyridine amine compound as shown in a formula (I), a preparation method thereof, a pharmaceutical composition taking the compound as an active ingredient, application of the 1, 6-naphthyridine amine compound in preparation of a medicine for treating cancer, application of the 1, 6-naphthyridine amine compound in preparation of a medicine for treating and / or preventing infectious diseases caused by mycobacterium tuberculosis and application of the 1, 6-naphthyridine amine compound in preparation of a fluorescent dye. Wherein R1, R2, R3 and A ring are described in the specification.

Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions comprising the 13-membered macrolides, and methods of treating infectious diseases, and in particular, disease resulting from Gram negative bacteria using the disclosed macrolides. Formula (I)

The present disclosure provides STING agonists, and compositions, formulations, and methods for treating diseases or disorders (e.g., cancer, inflammatory diseases, autoimmune diseases, and infectious diseases) with the STING agonists or compositions thereof.

The invention discloses a lateral flow biosensor for joint detection of SAA and CRP based on an AIE material and application, the lateral flow biosensor comprises a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad, the combination pad is coated with fluorescent nano-microsphere labeled antibodies AIE490NP-SAA, AIE490NP-RIgG and AIE610NP-CRP, and the nitrocellulose membrane is coated with fluorescent nano-microsphere labeled antibodies AIE490NP-RIgG and AIE610NP-CRP. A detection line T line and a quality control line C line are sprayed on the nitrocellulose membrane, the T line is formed by an SAA coating antigen and a CRP coating antigen which are coated on the nitrocellulose membrane, and the C line is formed by a goat anti-rabbit IgG antibody coated on the nitrocellulose membrane. The prepared lateral flow biosensor can simultaneously detect CRP and SAA, has high sensitivity and good repeatability, and has wide application prospects in differential diagnosis of early infectious diseases.

The inventions relates to Immunoglobulin A (IgA) or a pharmaceutical composition comprising IgA for use in the treatment of an infectious disease of or in an immune privileged organ, such as the eye, fetus, placenta, central nervous system (CNS) and / or testicles caused by a bacterial, fungal, viral or parasitic infection, in particular caused by bacteria of the human microbiome. IgA-coated pathogens can be addressed by FCAR+ and / or CD11c+ innate immune cells, for example by phagocytosis, or by activation of the complement system. The use of IgA or a pharmaceutical composition comprising IgA in immune privileged sites is advantageous because in contrast to IgG, IgA-coated pathogens do not trigger activation of C1q, a protein used for the controlled pruning of synapses. This prevents neuronal damage in said immune privileged organ(s), while at the same time allowing an antibody-mediated immune response in said organs.

The present invention relates to the field of adoptive immune cell therapy, in particular adoptive T cell therapy. The present invention provides a conversion receptor which is capable of effectively converting an immunosuppressive signal of TGF [beta], which is normally present in the hostile tumor environment of a solid tumor, into a co-stimulatory signal, thereby improving T cell activation, and which can be safely used in therapy. Also provided are nucleic acids encoding the transforming receptors, cells expressing the receptors and pharmaceutical compositions comprising the cells, in particular for the treatment of cancer or infectious diseases, such as adoptive T cell therapy by solid tumors.

An immunosuppressant having the structure of formula (I), and a preparation method therefor and the use thereof are provided. The series of compounds can be widely used in the preparation of drugs for preventing and / or treating cancers or tumors, immune-related diseases and disorders, communicable diseases, infectious diseases or metabolic diseases mediated by PD-1 / PD-L1 signal pathways, which drugs are expected to be developed into a new generation of PD-1 / PD-L1 inhibitors.

The present invention relates to an engineered cell comprising at least one chimeric antigen receptor (CAR) polypeptide and a switchable CAR in particular for use in the treatment of cancer, infectious disease or autoimmune disease, a pharmaceutical composition comprising the engineered cell and a kit comprising the engineered cell or at least two nucleic acids and / or vectors comprising a nucleotide sequence encoding the at least one CAR polypeptide or comprising a nucleotide sequence encoding the at least one switchable CAR polypeptide.

The present invention relates to inhibitors of ACSL4 and their use as medicines. So far, no potent and selective well-validated ACSL4 inhibitor has been described. The inventors have designed and studied compounds of formula (I) that inhibit selectively ACSL4 activity at sub-micromolar concentrations and have interesting anti-ferroptotic properties. The biological results obtained by the inventors on this series of compounds demonstrate the interest of using these ACSL4 inhibitors for therapeutic applications in diseases such as cancers, neurodegenerative diseases and infectious diseases. In particular, the present invention relates to compounds of formula (I) and their use in a method of therapeutic treatment of a subject.

An immunological analysis mode of a novel total antibody assay and a kit for detecting antibodies of infectious diseases in human blood samples according to the mode, the kit comprising: a first reagent containing at least one antigen coated on a solid support and an anti-human IgM antibody coated on a solid support; and a second reagent containing at least one labeled antigen and a labeled anti-human IgG antibody; wherein at least one antigen of the at least one antigen coated on the solid support and at least one antigen of the at least one labeled antigen can bind to the same IgG antibody or the same IgM antibody in the sample. The kit can overcome the disadvantages caused by the detection principle while retaining the advantages of each detection principle. In addition, a method for detecting antibodies produced after pathogen infection in a sample is provided.

The present invention relates to a polysubstituted imidazolo[4,5-c][1,2]thiazine derivative and a use of an agent comprising same as an active agent, which is useful for infectious diseases associated with vascular inflammation caused by HMGB1 protein activity. It has been found that the polysubstituted imidazolo[4,5-c][1,2]thiazine derivative of the present invention increases the sepsis survival rate as a result of searching for antiseptic effects through CLP-induced sepsis animal experiments. Accordingly, the agent comprising the polysubstituted imidazolo[4,5-c][1,2]thiazine derivative or a pharmaceutically acceptable salt thereof as an active agent may be advantageously used as a therapeutic agent for infectious diseases and vascular inflammatory diseases including sepsis caused by HMGB1 protein activity.

The present invention pertains to the anti-inflammatory therapeutic effect of xantohumol in spinal cord injury (SCI). The continuous administration of xanthohumol for 1-8 weeks to SCI rats resulted in improved results in 4 clinical tests used and in lowering and faster elimination of macrophages from the SCI lesion. Since the infiltration of the SCI lesion by numerous phagocytic macrophages indicates a severe destructive inflammation of extraordinary longevity, administration of xanthohumol is neuroprotective and resulted in a better and faster recovery of the locomotor function and the strength and sensory function in the hind limbs, in a shorter period of paralysis of the urinary bladder and in the recovery of the body weight lost due to the SCI surgery. Since the traumatic brain injury (TBI) involving the white matter, and stroke involving the white matter initiate the severe destructive inflammation as in the SCI, the administration of xanthohumol is expected to be anti-inflammatory and neuroprotective in both brain diseases. Since neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia and Parkinson's disease, immune mediated neuroinflammation including multiple sclerosis and neuromyelitis optica and cerebrospinal infections have inflammatory pathogenesis involving microgliosis and infiltration by macrophages, the administration of xanthohumol is expected to result in therapeutic inhibition of progression of all above diseases as well as of related neurodegenerative, immune mediated and infectious diseases of the brain and of the spinal cord.

Provided herein are methods for preparing oxepanoprolines and associated synthetic intermediates. These routes allow access to oxepanoprolinamide antibiotics, which are lincosamide analogues useful for the treatment and prevention of infectious diseases. The methods are scalable and provide access to multigram quantities of the oxepanoproline (southern) fragments of the oxepanoprolinamide antibiotics.